122 related articles for article (PubMed ID: 15821045)
41. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
Chang TK; Yu L; Maurel P; Waxman DJ
Cancer Res; 1997 May; 57(10):1946-54. PubMed ID: 9157990
[TBL] [Abstract][Full Text] [Related]
42. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
[TBL] [Abstract][Full Text] [Related]
43. CYP3A4 is a human microsomal vitamin D 25-hydroxylase.
Gupta RP; Hollis BW; Patel SB; Patrick KS; Bell NH
J Bone Miner Res; 2004 Apr; 19(4):680-8. PubMed ID: 15005856
[TBL] [Abstract][Full Text] [Related]
44. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
[TBL] [Abstract][Full Text] [Related]
45. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
Ghosal A; Lu X; Penner N; Gao L; Ramanathan R; Chowdhury SK; Kishnani NS; Alton KB
Drug Metab Dispos; 2011 Jan; 39(1):30-8. PubMed ID: 20926621
[TBL] [Abstract][Full Text] [Related]
46. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ
Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956
[TBL] [Abstract][Full Text] [Related]
47. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
48. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
49. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
[TBL] [Abstract][Full Text] [Related]
50. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.
Lin YS; Dowling AL; Quigley SD; Farin FM; Zhang J; Lamba J; Schuetz EG; Thummel KE
Mol Pharmacol; 2002 Jul; 62(1):162-72. PubMed ID: 12065767
[TBL] [Abstract][Full Text] [Related]
51. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
52. Small interfering RNA-mediated silencing of cytochrome P450 3A4 gene.
Chen J; Yang XX; Huang M; Hu ZP; He M; Duan W; Chan E; Sheu FS; Chen X; Zhou SF
Drug Metab Dispos; 2006 Sep; 34(9):1650-7. PubMed ID: 16760227
[TBL] [Abstract][Full Text] [Related]
53. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
[TBL] [Abstract][Full Text] [Related]
54. Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations.
Barter ZE; Perrett HF; Yeo KR; Allorge D; Lennard MS; Rostami-Hodjegan A
Biopharm Drug Dispos; 2010 Nov; 31(8-9):516-32. PubMed ID: 21104927
[TBL] [Abstract][Full Text] [Related]
55. The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine.
Topletz AR; Dennison JB; Barbuch RJ; Hadden CE; Hall SD; Renbarger JL
Drug Metab Dispos; 2013 Sep; 41(9):1651-61. PubMed ID: 23780963
[TBL] [Abstract][Full Text] [Related]
56. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites.
Woodland C; Ito S; Granvil CP; Wainer IW; Klein J; Koren G
Life Sci; 2000 Nov; 68(1):109-17. PubMed ID: 11132240
[TBL] [Abstract][Full Text] [Related]
57. Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites.
Oda Y; Kharasch ED
J Pharmacol Exp Ther; 2001 Apr; 297(1):410-22. PubMed ID: 11259570
[TBL] [Abstract][Full Text] [Related]
58. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
59. Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar).
Ghosal A; Chowdhury SK; Tong W; Hapangama N; Yuan Y; Su AD; Zbaida S
Drug Metab Dispos; 2006 Apr; 34(4):628-35. PubMed ID: 16443667
[TBL] [Abstract][Full Text] [Related]
60. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.
Chang TK; Weber GF; Crespi CL; Waxman DJ
Cancer Res; 1993 Dec; 53(23):5629-37. PubMed ID: 8242617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]